Navigation Links
Finding the Achilles' heel of cancer
Date:12/10/2009

A never-approved drug developed to prevent the death of nerve cells after a stroke can efficiently kill cancer cells while keeping normal cells healthy and intact, an international team led by a Tel Aviv University researcher is reporting in the journal Breast Cancer Research.

Prof. Malka Cohen-Armon of TAU's Sackler School of Medicine found that the stroke drug a member of a family of phenanthridine derivatives developed by an American drug company worked to kill cancer in mice which had been implanted with human breast cancer cells.

"Not only did the drug kill the cancer, but when we investigated normal cells, we discovered that they'd reacted as though they hadn't come in contact with the drug," says Prof. Cohen-Armon. "This is the result we were hoping for. If human trials go well, we could have an entirely new class of drugs in our hands for the fight against cancer."

Stopping the deadly cycle of cancer cell growth

The immediate results of the study were only one of the promising findings in her research, she notes. The team also discovered a molecular mechanism in the cell cycle that can be arrested only in human cancer cells. This cell cycle arrest, they report, causes the cancer cells to die without affecting normal human cells.

"We've found a molecular triggering mechanism in cancer cells that, when set off, causes the cancer cells to die ― they just stop multiplying and die within 48 to 72 hours. Normal, healthy body cells are only temporarily arrested by the same mechanism ― they overcome this cell cycle arrest within 12 hours and continue to proliferate in the presence of the drug as normal un-treated cells," says Prof. Cohen-Armon. "All the human cancer cells we tested seemed to succumb to this compound."

She adds that, even if this particular drug doesn't reach the market to fight against cancer, an entirely new class of drugs might be built around mechanism the team has revealed.

Different strokes

The stroke drug was initially developed to prevent nerve cell death during inflammation and tissue damage in the brain after stroke. However, in pre-clinical studies, American researchers found that these compounds didn't work as well as they'd hoped. Today they are used only for research purposes in laboratory settings.

"The compound we used," says Prof. Cohen-Armon, "presented no traces of toxicity in mice. With this compound, we were able to show how one of the many molecular mechanisms regulating the cell cycle can be targeted, and the proliferation of cancer cells halted." The team is currently working to identify all the regulatory mechanisms involved in this specific process and hope that, in better understanding the science, they might point the way to a new class of anti-cancer drugs.

Her research team was joined by Asher Kastiel, a Ph.D. student from Prof. Shai Izraeli's team working at the Chaim Sheba Medical Center, and the veterinarian Dr. David Castel. All the experiments conform with the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health in the United States.


'/>"/>

Contact: George Hunka
ghunka@aftau.org
212-742-9070
American Friends of Tel Aviv University
Source:Eurekalert  

Related medicine news :

1. Many Parents Share Genetic Test Findings With Kids
2. New Alzheimers findings: High stress and genetic risk factor lead to increased memory decline
3. New MRI finding sheds light on multiple sclerosis disease progressio
4. High and mighty: first common height gene identified by researchers behind obesity gene finding
5. Scientists, physicians present latest findings in personalized cancer treatment and prevention
6. Health psychologists discuss latest research findings
7. Incidental findings found when radiologists take a broader look at renal MRA
8. First significant genetic finding in severe PMS, or PMDD
9. Chair of U.S. Preventive Services Task Force Pledges to Recommend Re-evaluation of Recent Glaucoma Findings
10. The Organic Trade Association Hails Preliminary Research Findings Showing Nutritional Benefits of Organic Products
11. Key findings for all veterans seen in depression and suicide study
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Finding the Achilles' heel of cancer
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media ... Pro X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice ... X users can now reveal the media of their split screens with growing ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... strategic partnership with Connance, a healthcare industry leader providing predictive analytics to ... technology combine to provide health systems, hospitals and ambulatory surgical centers with ...
(Date:6/27/2016)... ... 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to Best Buy ... in the United States and Canada wear eyeglasses. Once considered to be a purely ... make a fashion statement. Even celebrities use glasses as a way of creating an ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/26/2016)... Cary, North Carolina (PRWEB) , ... June 26, 2016 , ... ... the release of a new product that was developed to enhance the health of ... harvested for centuries. , The two main herbs in the PawPaws Cat Kidney ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
Breaking Medicine Technology: